XML 66 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Schedule of Fair Value Measurements

    Carrying     Fair Value Measurement Using
    Value     Level 1     Level 2    
Investments in Equity Securities                          
Adhera Therapeutics – Convertible Series E Preferred Shares   $ 1,769,300     $    -     $    -    
    $ 1,769,300     $ -     $ -    

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive:

 

    Nine and three months ended  
   

September

30, 2019

   

September 30,

2018

 
             
Convertible notes     10,000,000       -  
Stock options     6,145,044       6,786,000  
Warrants     19,515,787       24,381,000  
Potentially dilutive securities     35,660,831       31,167,000